|
|
β6‐integrin serves as a novel serum tumor marker for colorectal carcinoma |
|---|---|
| Author: | Bengs, Susan1; Becker, Eugenia1; Busenhart, Philipp1; |
| Organizations: |
1Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland 2Department of Immunology, Stanford University, Stanford, CA 3National Center for Cancer Care and Research NCCCR, Hamad Medical Corporation, Doha, Qatar
4Cancer and Translational Medicine Research Unit, Department of Pathology, University of Oulu, Oulu, Finland
5Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland 6Department of Gastroenterology, University Hospital, Basel, Switzerland 7Department of Visceral and Transplant Surgery, University and University Hospital Zurich, Zürich, Switzerland 8Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland 9Clinic for Gastroenterology Bethanien, Zürich, Switzerland 10Clinic for Gastroenterology Zurich-Fluntern, Zurich, Switzerland 11Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom 12Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, CA 13Department of Surgery, University Hospital Magdeburg, Magdeburg, Germany 14Department of Medical Informatics, University of Erlangen-Nuremberg, Erlangen, Germany 15Division of Molecular and Experimental Surgery, University Medical Center Erlangen, Erlangen, Germany 16Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland |
| Format: | article |
| Version: | accepted version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1.1 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2019040911662 |
| Language: | English |
| Published: |
John Wiley & Sons,
2019
|
| Publish Date: | 2019-04-09 |
| Description: |
AbstractColorectal cancer (CRC) is one of the leading causes of cancer‐related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This study aims to identify β6‐integrin (ITGB6) as a novel serum tumor marker for diagnosis, prognosis, and surveillance of CRC. ITGB6 serum levels were validated in retro‐ and prospective CRC patient cohorts. ITGB6 serum levels were analyzed by ELISA. Using an initial cohort of 60 CRC patients, we found that ITGB6 is present in the serum of CRC, but not in non‐CRC control patients. A cut‐off of ≥2 ng/mL ITGB6 reveals 100% specificity for the presence of metastatic CRC. In an enlarged study cohort of 269 CRC patients, ITGB6 predicted the onset of metastatic disease and was associated with poor prognosis. Those data were confirmed in an independent, prospective cohort consisting of 40 CRC patients. To investigate whether ITGB6 can also be used for tumor surveillance, serum ITGB6‐levels were assessed in 26 CRC patients, pre‐ and post‐surgery, as well as during follow‐up visits. After complete tumor resection, ITGB6 serum levels declined completely. During follow‐up, a new rise in ITGB6 serum levels indicated tumor recurrence or the onset of new metastasis as confirmed by CT scan. ITGB6 was more accurate for prognosis of advanced CRC and for tumor surveillance as the established marker carcinoembryonic antigen (CEA). Our findings identify ITGB6 as a novel serum marker for diagnosis, prognosis, and surveillance of advanced CRC. This might essentially contribute to an optimized patient care. see all
|
| Series: |
International journal of cancer |
| ISSN: | 0020-7136 |
| ISSN-E: | 1097-0215 |
| ISSN-L: | 0020-7136 |
| Volume: | 145 |
| Issue: | 3 |
| Pages: | 678 - 685 |
| DOI: | 10.1002/ijc.32137 |
| OADOI: | https://oadoi.org/10.1002/ijc.32137 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3111 Biomedicine |
| Subjects: | |
| Funding: |
Grant sponsors: Deutsche Forschungsgemeinschaft; Foundation for Scientific Research at the University of Zurich; Hartmann-Müller Foundation; Promedica Foundation, Chur; Stiftung Experimentelle Biomedizin; Swiss National Science Foundation; The German Research Foundation; Grant numbers: SFB/TRR241, DFG, RU2438; The Foundation for Scientific Research at the University of Zurich; The Hartmann-Müller Foundation; The Promedica Foundation, Chur; The Swiss National Science Foundation; Grant numbers: CRSII3 154488/1, 314730_166381, 314730_146204; Stiftung Experimentelle Biomedizin. |
| Copyright information: |
© 2019 UICC. This is the peer reviewed version of the following article: Bengs, S. , Becker, E. , Busenhart, P. , Spalinger, M. R., Raselli, T. , Kasper, S. , Lang, S. , Atrott, K. , Mamie, C. , Vavricka, S. R., Boehmer, L. , Knuth, A. , Tuomisto, A. , Mäkinen, M. J., Hruz, P. , Turina, M. , Rickenbacher, A. , Petrowsky, H. , Weber, A. , Frei, P. , Halama, M. , Jenkins, G. , Sheppard, D. , Croner, R. S., Christoph, J. , Britzen‐Laurent, N. , Naschberger, E. , Schellerer, V. , Stürzl, M. , Fried, M. , Rogler, G. and Scharl, M. (2019), β6‐integrin serves as a novel serum tumor marker for colorectal carcinoma. Int. J. Cancer. doi:10.1002/ijc.32137, which has been published in final form at https://doi.org/10.1002/ijc.32137. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |